The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company’s global portfolio of hemostasis products.

Johns Hopkins has demonstrated in animals that applying a pacemaker’s mild electrical shocks to push the heart in and out of normal synchronized contraction for part of each day may be an effective way to slow down the progression of heart failure.

January 4, 2016 — In a comparison of bleeding complications and mortality between transradial and transfemoral stent placement following a heart attack, researchers from the Perelman School of Medicine at the University of Pennsylvania found those at risk for more bleeding were often treated with the riskier transfemoral approach. – a demonstration of the so-called risk-treatment paradox. The findings, from the largest study of its kind, were detailed in the Dec.

December 31, 2015 — The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in February to discuss and gather public recommendations on clinical trial, post-approval study design and physician training requirements for leadless cardiac pacemaker device technology.  The meeting will take place Thursday, Feb. 18, 2016, from 8 a.m. to 6 p.m. at the Hilton Washington DC North/Gaithersburg, Salons A, B, C, and D, 620 Perry Pkwy., Gaithersburg, MD,  20877.